ATORXS Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Alligator Bioscience AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.80 |
52 Week High | SEK 0.80 |
52 Week Low | SEK 0.80 |
Beta | 1.15 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -91.53% |
5 Year Change | -97.66% |
Change since IPO | -97.75% |
Recent News & Updates
Recent updates
Shareholder Returns
ATORXS | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | -0.2% | 0.5% |
1Y | n/a | -25.8% | 2.7% |
Return vs Industry: Insufficient data to determine how ATORXS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ATORXS performed against the UK Market.
Price Volatility
ATORXS volatility | |
---|---|
ATORXS Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ATORXS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ATORXS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 58 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, an agonistic antibody that targets CD40, which is in phase 2 clinical trail for the treatment solid metastatic tumors, initially pancreatic cancer; and ATOR-4066, a bispecific antibody tumor-specific immune effect, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ATOR-1017, a 4-1BB for solid metastatic tumors which is in Phase 1 clinical trial; and ALG
Alligator Bioscience AB (publ) Fundamentals Summary
ATORXS fundamental statistics | |
---|---|
Market cap | SEK 384.75m |
Earnings (TTM) | -SEK 212.87m |
Revenue (TTM) | SEK 40.45m |
9.5x
P/S Ratio-1.8x
P/E RatioIs ATORXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ATORXS income statement (TTM) | |
---|---|
Revenue | SEK 40.45m |
Cost of Revenue | SEK 169.05m |
Gross Profit | -SEK 128.59m |
Other Expenses | SEK 84.28m |
Earnings | -SEK 212.87m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Jul 13, 2023
Earnings per share (EPS) | -0.34 |
Gross Margin | -317.87% |
Net Profit Margin | -526.20% |
Debt/Equity Ratio | 0% |
How did ATORXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/06/19 15:22 |
End of Day Share Price | 2023/03/22 00:00 |
Earnings | 2023/03/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alligator Bioscience AB (publ) is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ingrid Gafanhão | Kempen & Co. NV |
Carl Ramanius | Redeye |